Why the study?
High blood pressure is a leading cause of CVD morbidity and mortality worldwide that disproportionately affects US racial/ethnic populations.
The review highlights the 2025 AHA/ACC High Blood Pressure Guideline's shift toward race-neutral risk assessment and community-engaged strategies to mitigate racial and ethnic disparities in hypertension outcomes.
Answers are grounded in this paper and cite their sources.
May support population-level hypertension prevention; leaves open effects on racial/ethnic disparities in outcomes.
Purpose of Review High blood pressure is a leading cause of cardiovascular disease (CVD) morbidity and mortality worldwide, disproportionately affecting racial/ethnic populations in the United States (US). This review summarizes racial/ethnic inequities in CVD risk, hypertension (HTN), and the social determinants or drivers of health (SDOH), highlighting the 2025 American Heart Association/American College of Cardiology (AHA/ACC) High Blood Pressure Guideline. Recent Findings Certain US racial/ethnic populations experience disproportionate HTN burden, with Black adults demonstrating higher rates of resistant, nocturnal and masked HTN, hypertensive disorders of pregnancy, and dementia and cognitive decline. The 2025 AHA/ACC High Blood Pressure Guideline emphasizes the use of a novel race-neutral CVD risk calculator to guide initiation of pharmacotherapy, utilizing patient counseling and shared decision-making, alongside team-based, community-engaged HTN management strategies. Summary The 2025 AHA/ACC High Blood Pressure Guideline advances health equity, integrating the SDOH into improved CVD risk assessment and management recommendations. Effective mitigation of disparities to improve blood pressure and CVD outcomes demands optimizing healthcare access, addressing systemic discrimination, incorporating social context into shared clinical-decision making, and deploying culturally-tailored, community-based interventions.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) conducted a review in Disadvantaged racial/ethnic populations in the United States with hypertension or high blood pressure. Potassium-based salt substitutes, intensive blood pressure lowering therapy, low-dose aspirin in hypertensive pregnant women, single-pill combination antihypertensive therapy vs. Regular salt (for salt substitute trials), standard blood pressure targets or therapy was evaluated on Reduction in cardiovascular events, stroke, major cardiovascular events, maternal morbidity and mortality, blood pressure control rates (51% reduction in risk of developing hypertension with potassium salt substitute in Peru; lower stroke and CV event rates in China trial with potassium salt substitute).
Synapse has enriched 10 related papers. Consider them for comparative context: